Actively Recruiting
Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma
Led by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Updated on 2023-07-25
360
Participants Needed
19
Research Sites
284 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a real world study aiming to observe the efficacy and safety of Anlotinib capsules in patients with advanced medullary thyroid carcinoma, and to summarize the treatment experience in a broad population of patients.
CONDITIONS
Official Title
Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients voluntarily joined the study, signed the informed consent, and had good compliance
- Patients aged 18 years or older at the time of signing the informed consent; ECOG Performance Status score 0-2; expected survival more than 3 months
- Pathologically confirmed inoperable locally advanced or metastatic medullary thyroid carcinoma with imaging or clinical evidence of disease progression within 14 months before enrollment
- At least one measurable lesion assessed by RECIST 1.1
- Major organ functions meet criteria within 7 days prior to treatment, including hemoglobin ≥85g/L, absolute neutrophil count ≥1.5×10⁹/L, platelets ≥80×10⁹/L
- Biochemical tests within limits: total bilirubin ≤1.5 times upper limit of normal, ALT and AST ≤2.5×ULN (or ≤5×ULN if liver metastasis), serum creatinine ≤1.5×ULN or creatinine clearance rate ≥60ml/min
- Female patients of reproductive age agree to use birth control during study and for 6 months after; negative serum pregnancy test within 7 days prior to enrollment; non-lactating
- Male patients agree to use contraception during study and for 6 months after
You will not qualify if you...
- Patients with other malignancies within 3 years, except those with continuous 5-year disease-free survival after single operation or cured cervical carcinoma in situ, non-melanoma skin cancer, or superficial bladder tumors
- Major surgery, open biopsy, or significant traumatic injury within 28 days before treatment
- Severe or uncontrolled diseases including grade ≥2 myocardial ischemia, myocardial infarction, arrhythmia, congestive heart failure (NYHA grade ≥2)
- Active or uncontrolled severe infection (CTC AE grade ≥2)
- Renal failure requiring hemodialysis or peritoneal dialysis
- Concomitant diseases judged by investigators to seriously endanger safety or interfere with study completion
- Prior use of Anlotinib hydrochloride capsules or similar VEGFR-TKI small molecule drugs such as vandetanib, cabozantinib, lenvatinib, sunitinib, sorafenib
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 19 locations
1
Anhui Provincial Cancer Hospital
Hefei, Anhui, China, 230031
Not Yet Recruiting
2
Beijing Tongren Hospital Affiliated to Capital Medical University
Beijing, Beijing Municipality, China, 100005
Actively Recruiting
3
Gansu Cancer Hospital
Lanzhou, Gansu, China, 730050
Actively Recruiting
4
Guangxi Zhuang Autonomous Region Cancer Hospital (Affiliated Cancer Hospital of Guangxi Medical University)
Nanning, Guangxi, China, 530021
Not Yet Recruiting
5
The First Affiliated Hospital of Hebei North University
Shijiazhuang, Hebei, China, 050051
Actively Recruiting
6
Tianjin Cancer Hospital
Tianjin, Hebei, China, 300181
Actively Recruiting
7
Henan Cancer Hospital
Zhengzhou, Henan, China, 450003
Actively Recruiting
8
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China, 450052
Actively Recruiting
9
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China, 430030
Actively Recruiting
10
Hubei Cancer Hospital
Wuhan, Hubei, China, 430079
Actively Recruiting
11
Hunan Cancer Hospital
Changsha, Hunan, China, 410031
Not Yet Recruiting
12
Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University
Nanjing, Jiangsu, China, 210008
Actively Recruiting
13
Jiangsu North People's Hospital
Yangzhou, Jiangsu, China, 225003
Actively Recruiting
14
Liaoning Cancer Hospital and Institute
Shenyang, Liaoning, China, 110801
Actively Recruiting
15
The First Affiliated Hospital of Xi'an Jiaotong University
Xi’an, Shanxi, China, 710061
Actively Recruiting
16
Shanxi Provincial Tumor Hospital
Xi’an, Shanxi, China, 710065
Not Yet Recruiting
17
Tianjin People's Hospital
Tianjin, Tianjin Municipality, China, 300122
Actively Recruiting
18
The First Affiliated Hospital of Kunming Medical University
Kunming, Yunnan, China, 650032
Actively Recruiting
19
Zhejiang Provincial People's Hospital
Hangzhou, Zhejiang, China, 314408
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here